This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.

3sfi

From Proteopedia

(Difference between revisions)

Jump to: navigation, search

Current revision

Ethionamide Boosters Part 2: Combining Bioisosteric Replacement and Structure-Based Drug Design to Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors.

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/3sfi"

@@ Line 3: / Line 3: @@
 <StructureSection load='3sfi' size='340' side='right'caption='[[3sfi]], [[Resolution|resolution]] 2.31&Aring;' scene=''>
 == Structural highlights ==
-<table><tr><td colspan='2'>[[3sfi]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/"bacillus_tuberculosis"_(zopf_1883)_klein_1884 "bacillus tuberculosis" (zopf 1883) klein 1884]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3SFI OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3SFI FirstGlance]. <br>
+<table><tr><td colspan='2'>[[3sfi]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Mycobacterium_tuberculosis Mycobacterium tuberculosis]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3SFI OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3SFI FirstGlance]. <br>
-</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=3SF:5,5,5-TRIFLUORO-1-{4-[3-(1,3-THIAZOL-2-YL)-1,2,4-OXADIAZOL-5-YL]PIPERIDIN-1-YL}PENTAN-1-ONE'>3SF</scene></td></tr>
+</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.31&#8491;</td></tr>
-<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[3o8g|3o8g]], [[3o8h|3o8h]], [[3g1l|3g1l]], [[3g1m|3g1m]], [[1u9n|1u9n]]</div></td></tr>
+<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=3SF:5,5,5-TRIFLUORO-1-{4-[3-(1,3-THIAZOL-2-YL)-1,2,4-OXADIAZOL-5-YL]PIPERIDIN-1-YL}PENTAN-1-ONE'>3SF</scene></td></tr>
-<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">ethR, MT3970, RV3855 ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=1773 "Bacillus tuberculosis" (Zopf 1883) Klein 1884])</td></tr>
 <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3sfi FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3sfi OCA], [https://pdbe.org/3sfi PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3sfi RCSB], [https://www.ebi.ac.uk/pdbsum/3sfi PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3sfi ProSAT]</span></td></tr>
 </table>
 == Function ==
-[[https://www.uniprot.org/uniprot/ETHR_MYCTU ETHR_MYCTU]] Involved in the repression of the monooxygenase EthA which is responsible of the formation of the active metabolite of ethionamide (ETH).<ref>PMID:10869356</ref> <ref>PMID:10944230</ref>
+[https://www.uniprot.org/uniprot/ETHR_MYCTU ETHR_MYCTU] Involved in the repression of the monooxygenase EthA which is responsible of the formation of the active metabolite of ethionamide (ETH).<ref>PMID:10869356</ref> <ref>PMID:10944230</ref>
-<div style="background-color:#fffaf0;">
-== Publication Abstract from PubMed ==
-Mycobacterial transcriptional repressor EthR controls the expression of EthA, the bacterial monooxygenase activating ethionamide, and is thus largely responsible for the low sensitivity of the human pathogen Mycobacterium tuberculosis to this antibiotic. We recently reported structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors leading to the discovery of potent ethionamide boosters. Despite high metabolic stability, pharmacokinetic evaluation revealed poor mice exposure; therefore a second phase of optimization was required. Herein structure-property relationships study is reported according to the replacement of the two aromatic heterocycles: 2-thienyl and 1,2,4-oxadiazolyl moieties. This work was done using a combination of structure-based drug design and in vitro/ex vivo evaluations of ethionamide boosters on the targeted protein EthR and on the human pathogen Mycobacterium tuberculosis. Thanks to this process, we identified compound 42 (BDM41906) which displays improved efficacy, in addition to high exposure of mice after oral administration.
-Ethionamide Boosters Part 2: Combining Bioisosteric Replacement and Structure-Based Drug Design to Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors.,Flipo M, Desroses M, Lecat-Guillet N, Villemagne B, Blondiaux N, Leroux F, Piveteau C, Mathys V, Flament MP, Siepmann J, Villeret V, Wohlkonig A, Wintjens R, Soror SH, Christophe T, Jeon HK, Locht C, Brodin P, Deprez BP, Baulard A, Willand N J Med Chem. 2011 Nov 20. PMID:22098589<ref>PMID:22098589</ref>
-From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-</div>
-<div class="pdbe-citations 3sfi" style="background-color:#fffaf0;"></div>
 ==See Also==
@@ Line 28: / Line 18: @@
 </StructureSection>
 [[Category: Large Structures]]
-[[Category: Baulard, A R]]
+[[Category: Mycobacterium tuberculosis]]
-[[Category: Blondiaux, N]]
+[[Category: Baulard AR]]
-[[Category: Brodin, P]]
+[[Category: Blondiaux N]]
-[[Category: Christophe, T]]
+[[Category: Brodin P]]
-[[Category: Desroses, M]]
+[[Category: Christophe T]]
-[[Category: Flament, M P]]
+[[Category: D prez B]]
-[[Category: Flipo, M]]
+[[Category: Desroses M]]
-[[Category: Jeon, H K]]
+[[Category: Flament MP]]
-[[Category: Lecat-Guillet, N]]
+[[Category: Flipo M]]
-[[Category: Leroux, F]]
+[[Category: Jeon HK]]
-[[Category: Locht, C]]
+[[Category: Lecat-Guillet N]]
-[[Category: Mathys, V]]
+[[Category: Leroux F]]
-[[Category: Piveteau, C]]
+[[Category: Locht C]]
-[[Category: Siepmann, J]]
+[[Category: Mathys V]]
-[[Category: Soror, S H]]
+[[Category: Piveteau C]]
-[[Category: Villemagne, B]]
+[[Category: Siepmann J]]
-[[Category: Villeret, V]]
+[[Category: Soror SH]]
-[[Category: Willand, N]]
+[[Category: Villemagne B]]
-[[Category: Wintjens, R]]
+[[Category: Villeret V]]
-[[Category: Wohlkonig, A]]
+[[Category: Willand N]]
-[[Category: Prez, B D]]
+[[Category: Wintjens R]]
-[[Category: Dna]]
+[[Category: Wohlkonig A]]
-[[Category: Dna binding protein]]
-[[Category: Inhibitor]]
-[[Category: Tetr-family]]
-[[Category: Transcription repressor-inhibitor complex]]
-[[Category: Transcritptional regulatory repressor]]

3sfi

From Proteopedia

Current revision

Ethionamide Boosters Part 2: Combining Bioisosteric Replacement and Structure-Based Drug Design to Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors.

Structural highlights

Function

See Also

References

Contents

Proteopedia Page Contributors and Editors (what is this?)

Views

Personal tools

Navigation

Search

Toolbox